Processa Pharmaceuticals, Inc. Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
Processa Pharmaceuticals, Inc. (PCSA) had Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount of $2.43 million as of 2021-12-31, per its 10-K filed 2022-03-30.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized · last filed 2022-03-30
- 2021-12-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $2.43M.
- 2019-12-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $1.45M.
- 2018-12-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $754.88K.
- 2018-09-30: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $649.91K.
| Period end | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount |
|---|---|
| 2021-12-31 | $2.43M 10-K · filed 2022-03-30 |
| 2019-12-31 | $1.45M 10-K · filed 2020-03-06 |
| 2018-12-31 | $754.88K 10-K/A · filed 2019-04-08 |
| 2018-09-30 | $649.91K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |